Real-world evaluation of bebtelovimab effectiveness during the period of COVID-19 Omicron variants, including BA.4/BA.5
ABSTRACT: Objectives: Bebtelovimab is an anti-SARS-CoV-2 monoclonal antibody active against Omicron lineage variants authorized to treat high-risk outpatients with COVID-19. We sought to determine the real-world effectiveness of bebtelovimab during the Omicron phases BA.2/BA2.12.1/BA4/BA5. Methods:...
Guardat en:
| Autors principals: | , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Elsevier
2023-07-01
|
| Col·lecció: | International Journal of Infectious Diseases |
| Matèries: | |
| Accés en línia: | http://www.sciencedirect.com/science/article/pii/S1201971223005258 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|